← Back
$TEVA All transactions

TEVA PHARMACEUTICAL INDUSTRIES LTD

▼ SELL 10b5-1 Plan

$ Value

$448K

Shares

14,150

Price

$32

Filed

Mar 9

Insider

Name

Jover Placid

Title

See "Remarks"

CIK

0002026165

Roles

Officer

Transaction Details

Transaction Date

2026-03-05

Code

S

Table

Non-Derivative

Ownership

Direct

Equity Swap

No

Shares After

6,774

Footnotes

The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. | Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. | The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025. | Represents with respect to the vesting of restricted share units, the reporting person sold all such shares vested, including shares to cover tax witholding obligations in connection with the vesting. | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.26 to $32.34, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. | Restricted share units were granted on March 5, 2025, with 14,150 vesting on each of March 5, 2026, March 5, 2027 and March 5, 2028, and 14,153 vesting on March 5, 2029.

Filing Info

Accession No.

0001193125-26-098506

Form Type

4

Issuer CIK

0000818686

Jover Placid's History

Date Ticker Type Value
2026-03-05 TEVA M
2026-03-05 TEVA $448K
2026-03-05 TEVA M $0
2026-03-04 TEVA A $0
2025-08-01 TEVA M
2025-08-01 TEVA $92K
2025-08-01 TEVA M $0

Other Insiders at TEVA (90d)

Insider Bought Sold Last
Francis Richard D
President and CEO
$31.1M 2026-03-05
Sabag Mark
See "Remarks"
$1.9M 2026-03-17
Daniell Richard
EVP, Europe Commercial
$7.7M 2026-03-05
Daniell Richard
Exec. VP, European Commercial
2026-01-27
Kalif Eliyahu Sharon
EVP, Chief Financial Officer
$11.6M 2026-03-05
Weiss Amir
Chief Accounting Officer
2026-03-05
Hughes Eric A
See "Remarks"
$3.3M 2026-03-05
Fox Christine
EVP, U.S. Commercial
$546K 2026-03-05
Shields Matthew
EVP, Global Operations
$548K 2026-03-05
Jover Placid
See "Remarks"
2026-03-05
Lippman Evan
EVP, Business Development
2026-03-04
Savage Brian
Interim Chief Legal Officer
$164K 2026-03-05